Paid Clinical Trials Allentown

Discover 2,141 paid clinical trials in Allentown, Pennsylvania. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,141

A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Recruiting

PHASE2

PHASE3

Sponsor:

Cytokinetics

Location:

Philadelphia PA, Morristown NJ, New York NY, Washington DCshow 18 more

Code:

NCT06412666

Conditions

Pediatric

Symptomatic Obstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Aficamten

Placebo

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

New Brunswick NJ, New Hyde Park NY, Baltimore MD, Warwick RIshow 41 more

Code:

NCT04616326

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Galcanezumab

Placebo

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical PracticeA Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Recruiting

Sponsor:

Sarepta Therapeutics, Inc.

Location:

Philadelphia PA, Norfolk VA, London, Columbus OHshow 8 more

Code:

NCT04475926

Conditions

Limb-girdle Muscular Dystrophy

Eligibility Criteria

Sex: All

Age: 4+

Healthy Volunteers: Not accepted

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS PatientsStudy of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Recruiting

PHASE2

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Location:

Philadelphia PA, Bethesda MD, Houston TX

Code:

NCT06730126

Conditions

Autoimmune Lymphoproliferative Syndrome

Eligibility Criteria

Sex: All

Age: 16 - 70+

Healthy Volunteers: Not accepted

Interventions

Soquelitinib

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

PHASE3

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Philadelphia PA, New York NY, Neptune NJ, Bronx NYshow 45 more

Code:

NCT04045665

Conditions

Atrial Fibrillation

Stroke

Bleeding

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Antiplatelet-only strategy

Oral Anticoagulant plus background antiplatelet therapy

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Pottsville PA, Jenkintown PA, Media PA, Warren NJshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSAn Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Recruiting

Sponsor:

XenoPort, Inc.

Location:

Philadelphia PA, Amherst NY, Toledo OH, Columbia SCshow 8 more

Code:

NCT02560766

Conditions

RLS

Eligibility Criteria

Sex: All

Age: 13 - 17

Healthy Volunteers: Not accepted

Interventions

HORIZANT 300 mg

HORIZANT 600 mg

Placebo

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Allentown PA, Bethlehem PA, Quakertown PA, Easton PAshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Recruiting

PHASE1

PHASE2

Sponsor:

RayzeBio, Inc.

Location:

Philadelphia PA, New York NY, Buffalo NY, Pittsburg PAshow 18 more

Code:

NCT06590857

Conditions

Metastatic Breast Cancer

HER2-negative Breast Cancer

ER+ Breast Cancer

Advanced Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RYZ101

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsOpen Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Recruiting

PHASE2

Sponsor:

University of Pennsylvania

Location:

Philadelphia PA

Code:

NCT06066957

Conditions

Cytomegalovirus Infections

Transplant-Related Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Letermovir 480 MG [Prevymis]